TR200101353A2 - Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç - Google Patents

Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç

Info

Publication number
TR200101353A2
TR200101353A2 TR2001/01353A TR200101353A TR200101353A2 TR 200101353 A2 TR200101353 A2 TR 200101353A2 TR 2001/01353 A TR2001/01353 A TR 2001/01353A TR 200101353 A TR200101353 A TR 200101353A TR 200101353 A2 TR200101353 A2 TR 200101353A2
Authority
TR
Turkey
Prior art keywords
drug
preparation
treatment
solid tumors
stabilized paclitaxel
Prior art date
Application number
TR2001/01353A
Other languages
English (en)
Other versions
TR200101353A3 (tr
Inventor
Falciani Marco
Original Assignee
Acs Dobfar S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200101353(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar S.P.A. filed Critical Acs Dobfar S.P.A.
Publication of TR200101353A3 publication Critical patent/TR200101353A3/tr
Publication of TR200101353A2 publication Critical patent/TR200101353A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Paklitaksel'e duyarli kati tümörlerin tedavisi için bir ilacin hazirlanmasinda albümin ile kararli hale getirilmis paklitaksel mikro-taneciklerinin kullanimi ve böylece elde edilen ilaç ifsa edilmistir.
TR2001/01353A 2000-05-18 2001-05-15 Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç TR200101353A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (2)

Publication Number Publication Date
TR200101353A3 TR200101353A3 (tr) 2001-12-21
TR200101353A2 true TR200101353A2 (tr) 2001-12-21

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01353A TR200101353A2 (tr) 2000-05-18 2001-05-15 Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç

Country Status (23)

Country Link
US (1) US6652884B2 (tr)
EP (1) EP1155692B1 (tr)
JP (1) JP2001354559A (tr)
KR (2) KR20010105248A (tr)
CN (1) CN1198609C (tr)
AT (1) ATE267594T1 (tr)
AU (1) AU781517B2 (tr)
BR (1) BR0102040A (tr)
CA (1) CA2345482A1 (tr)
DE (1) DE60103453T2 (tr)
DK (1) DK1155692T3 (tr)
ES (1) ES2221874T3 (tr)
HK (1) HK1040368A1 (tr)
HU (1) HU229909B1 (tr)
IL (1) IL142674A0 (tr)
IT (1) ITMI20001107A1 (tr)
MX (1) MXPA01004980A (tr)
NO (1) NO330511B1 (tr)
NZ (1) NZ511201A (tr)
PT (1) PT1155692E (tr)
RU (1) RU2270003C2 (tr)
TR (1) TR200101353A2 (tr)
ZA (1) ZA200103755B (tr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
LT3248600T (lt) * 2005-02-18 2020-07-27 Abraxis Bioscience, Llc Terapinių agentų deriniai bei įvedimo būdai ir kombinuotas gydymas
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
CA2620585C (en) 2005-08-31 2015-04-28 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
EP1962906A4 (en) * 2005-10-21 2009-11-18 Panacea Biotec Ltd PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ANTICREME AND AT LEAST ONE POLYMER
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP2010520289A (ja) 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
SI2419732T1 (sl) 2009-04-15 2020-03-31 Abraxis Bioscience, Llc Sestave nanodelcev brez prionov in metode za njihovo pripravo
MX346861B (es) 2010-03-26 2017-04-04 Abraxis Bioscience Llc * Metodos de tratamiento de carcinoma hepato celular.
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
SG10201606406PA (en) 2011-04-28 2016-09-29 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
JP6387389B2 (ja) * 2013-03-13 2018-09-05 アブラクシス バイオサイエンス， エルエルシー 小児充実性腫瘍の処置の方法
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
CN109906088A (zh) * 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
CA3094453A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP0693924B2 (en) 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
IL133672A0 (en) * 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2000006152A1 (en) 1998-07-30 2000-02-10 Novopharm Biotech, Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
AU781517B2 (en) 2005-05-26
DK1155692T3 (da) 2004-08-09
TR200101353A3 (tr) 2001-12-21
ITMI20001107A0 (it) 2000-05-18
HK1040368A1 (en) 2002-06-07
DE60103453D1 (de) 2004-07-01
NZ511201A (en) 2002-11-26
IL142674A0 (en) 2002-03-10
NO20012409L (no) 2001-11-19
NO20012409D0 (no) 2001-05-16
US6652884B2 (en) 2003-11-25
ATE267594T1 (de) 2004-06-15
DE60103453T2 (de) 2005-06-23
MXPA01004980A (es) 2002-08-06
CN1324613A (zh) 2001-12-05
AU3876501A (en) 2001-11-22
CN1198609C (zh) 2005-04-27
US20010046961A1 (en) 2001-11-29
ES2221874T3 (es) 2005-01-16
CA2345482A1 (en) 2001-11-18
PT1155692E (pt) 2004-09-30
HU0102039D0 (en) 2001-07-30
RU2270003C2 (ru) 2006-02-20
EP1155692B1 (en) 2004-05-26
HUP0102039A3 (en) 2002-12-28
ITMI20001107A1 (it) 2001-11-18
EP1155692A1 (en) 2001-11-21
JP2001354559A (ja) 2001-12-25
NO330511B1 (no) 2011-05-09
KR20010105248A (ko) 2001-11-28
KR20080091747A (ko) 2008-10-14
BR0102040A (pt) 2002-03-19
HU229909B1 (en) 2014-12-29
ZA200103755B (en) 2001-11-15
HUP0102039A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
TR200101353A2 (tr) Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
TR200101262T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
TR199903278T2 (tr) 2-Substitüte 4,5-Diaril imidazoller.
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
FR10C0015I2 (fr) Molecules d'anticorps a specificite pour le facteur alpha de necrose tumorale humaine, et leurs utilisations
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
ATE497385T1 (de) Neue phenylalanin-derivate
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
AU7001001A (en) Modified forms of pharmacologically active agents and uses therefor
DE69925133D1 (de) Pyrrolobenzodiazepine
DE60022758D1 (de) Hautpflegezusammensetzung
DE60022756D1 (de) Hautpflegezusammensetzung
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
IT1301966B1 (it) Composizioni farmaceutiche ad attivita' analgesica
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
TR200400187T2 (tr) Yeni oral formülasyon.
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
TR200103710T2 (tr) Vajinal mukozayı etkileyen patolojilerin topikal tedavisinde kullanıma yönelik E vitamini
ATE273697T1 (de) Pharmazeutische levothyroxinzubereitung
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı